GSK, FTSE 100
FTSE 100 Live 10 October: GSK shares rise on $2.2bn Zantac settlement, property firm gets £1.1bn bid
GSK’s $2.2 billion Zantac settlement today put its shares top of the FTSE 100, albeit still well short of their level before litigation started in summer 2022. The drugs group rose 5% or 77.5p to 1535.
FTSE 100 Live: UK Stocks Fluctuate as GSK Gets Settlement Lift
FTSE 100 fluctuates after key US inflation report as the pound remains below $1.31
GSK resolves Zantac cancer claims with a £1.7 billion settlement, boosting shares
The pharmaceutical giant has agreed to a $2.2bn (£1.68bn) settlement to resolve lawsuits in the US alleging that the company's Zantac heartburn drug had caused cancer
Stocks give up gains; GSK jumps on $2.2bn Zantac settlement
GSK PLC will pay up to $2.2 billion to settle some 80,000 US lawsuits over its heartburn medication Zantac, generically known as ranitidine. The plaintiffs alleged the drug caused cancer, although GSK maintains there is no evidence linking Zantac to an increased cancer risk and has not admitted liability.
GSK reaches further two settlements regarding Zantac
GSK PLC on Wednesday said it reached two confidential settlements regarding the Zantac case in California State Court. The London-based pharmaceutical company said the cases concerned John Russell resolving his bladder cancer case,
UK mortgage default rates rise; GSK’s shares surge after $2.2bn Zantac settlement; Unilever finally quits Russia – business live
Lenders report that default rates on secured loans to UK households increased in Q3 2024 and are expected to increase again in Q4
GSK agrees to settle about 80,000 Zantac lawsuits for up to $2.2 billion
GSK has agreed to pay up to $2.2 billion to settle most lawsuits in US state courts claiming that a discontinued version of ...
Hosted on MSN4d
Here's Why GSK (GSK) is a Strong Value Stock
Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both. The popular research ...
McKnight's Long-Term Care News4d
RSV vaccine still 43.3 percent effective 3 years after people take it, trial shows
GSK announced on Tuesday that a single dose of its Arexvy vaccine against respiratory syncytial virus (RSV) was 43.3% ...
GlaxoSmithKline (GSK) Receives a Sell from J.P. Morgan
In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a ...
GSK shares jump after landmark £1.68bn heartburn drug settlement
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...
Sanofi’s Hudson Nears Goal of Splitting Off Consumer Health Unit
Sanofi is nearing the sale of its consumer health business to Clayton Dubilier & Rice, a year after Chief Executive Officer Paul Hudson announced plans to split off the division to concentrate on ...
FTSE 100 Little Changed; GSK Shares Surge Over 5%
U.K. stocks were little changed on Thursday despite a closely watched gauge of U.K. house prices turning positive for the first time ...